Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Maciej Wieczorek, PhD

Articles by Maciej Wieczorek, PhD

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, MD

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, PhD

ByMaciej Wieczorek, PhD

October 27th 2025

Maciej Wieczorek, MD, discusses CPL'36, a new PDA101 inhibitor with a novel mechanism of action for treatment of schizophrenia.

Latest Updated Articles

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, PhD
October 27th 2025

Trending on Psychiatric Times

The Real-World Burden of Adult ADHD

How Prevalent Is Simultaneous Alcohol-Cannabis Use?

Rapid Antidepressants and Suicide Risk: What Do We Really Know?

Why Extended-Release Stimulants Are First-Line for ADHD

"Improved" PDE10A Inhibitor Exhibits Antipsychotic Effect